Project Grant R01CA289881
Award Date
1/15/25
Completion Date
12/31/29
Dollars Obligated
$718K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Memphis, TN 38105, USA
Similar Awards
This federal Project Grant award from the Department of Health and Human Services National Institutes of Health National Cancer Institute, under the Cancer Cause and Prevention Research program (CFDA 93.393), provides $613,054 to St. Jude Children's Research Hospital Inc. to study the mechanisms by which transcription factors control different cell states in neuroblastoma, a high-risk pediatric tumor. The key objectives are to 1) interrogate how master transcription factors control the...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $738,024 to St. Jude Children's Research Hospital to develop chemical probes targeting the chromatin binding domains of the BPTF protein in neuroblastoma, an aggressive pediatric cancer. The goal is to functionally annotate the BPTF "reader" domains and use them as therapeutic leads. The research will involve optimizing BPTF bromodomain (BRD) inhibitors, developing BPTF...
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports research to understand the mechanisms by which a gene essential for rhabdoid tumor viability regulates chromatin function. The $148,568 award to St. Jude Children's Research Hospital will fund a 2.5-year project starting on Dec 25, 2024. The research aims to elucidate how loss of the target protein disrupts the balance between the SWI/SNF chromatin remodeling complex and the polycomb...
This $377,870 Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the development and validation of novel synthetic transcriptional repressors (STRs) capable of directly inhibiting the oncogenic transcription factor MYC. The grant aims to: 1) Optimize STR structures for high-affinity and specific binding to MYC target DNA sequences, 2) Enhance cellular and pharmacologic delivery of STRs while mapping their effects on epigenetic and...
This $431,968 Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research by Baylor College of Medicine to elucidate how the oncogene MYCN rewires the metabolic environment of neuroblastoma tumors to drive immune suppression, and to modulate this metabolic environment to enhance immune-based approaches for high-risk MYCN-amplified neuroblastoma. The research aims to uncover how MYCN amplification, a driver of aggressive neuroblastoma,...
The National Cancer Institute (NCI) awarded a $562,869 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to Children's Hospital Los Angeles (CHLA) to study the role of chromosome 17q gain in neuroblastoma malignancy. The 5-year project aims to: 1) compare the tumorigenic potential of 17q gain and MYCN in immature cells that give rise to sympathoadrenal cells; 2) determine genes on chromosome 17q that cooperate with MYCN to accelerate tumorigenesis and promote...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Research Manpower (CFDA 93.398) federal grant program, will support a clinical trial and correlative studies focused on improving CAR T-cell therapy for pediatric B-cell acute lymphoblastic leukemia (B-ALL). The award, totaling $289,458, will fund the following key products and services over the project period from Sep 1, 2024 to Aug 31, 2029: Conduct a Phase I clinical trial (MEMCAR19; NCT04881240) evaluating an...
This $788,589 Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports research by a pediatric neuro-oncologist at Children's Hospital Los Angeles (CHLA) to investigate the role of the FOXR2 transcription factor and ETS transcription factors in driving the formation of diffuse midline gliomas (DMGs), a devastating form of childhood brain cancer. The research aims to elucidate how aberrant FOXR2 expression cooperates with ETS factors to...
This Project Grant award for $1,340,665.00 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to St. Jude Children's Research Hospital Inc. The award supports research focused on the FGFR pathway as a lead therapeutic vulnerability in pediatric ependymoma, a type of brain cancer in children. The project will be conducted over 3 years, from September 1, 2023 to August 31, 2026, and aims to advance the development of effective...
This $503,194 Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports research at Seattle Children's Hospital aimed at developing an innovative multispecific T cell engager (MTE) therapy to treat neuroblastoma and other pediatric solid tumors. The key products and services being delivered under this 2-year award include: 1) Determining the efficacy of the R2P3 MTE, which binds to the ROR1 and PD-L1 tumor targets as well as CD3 on T cells,...